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Background: Radiation dermatitis occurs to some degree in most patients receiving radiotherapy, with or without
chemotherapy. Patients with squamous cell carcinoma of the head and neck (SCCHN) who receive radiotherapy in
combination with epidermal growth factor receptor (EGFR) inhibitors, such as cetuximab, may develop a characteristic
acne-like rash in addition to dermatitis.
Design: An advisory board of 11 experienced radiation oncologists, medical oncologists and dermatologists
discussed the management options for skin reactions in patients receiving EGFR inhibitors and radiotherapy for
SCCHN. Skin toxicity was categorised according to the National Cancer Institute—Common Terminology Criteria for
Adverse Events (version 3) grading.
Results: Both general and grade-specific approaches for the management of dermatitis in this patient group are
presented. It was concluded that where EGFR inhibitor-related acne-like rash and dermatitis coexist within irradiated
fields, management should be based on the grade of dermatitis: for grade 1 (or no dermatitis), treatment
recommendations for EGFR-related acne-like rash outside irradiated fields should be followed; for grades 2 and
above, treatment recommendations for dermatitis were proposed.
Conclusions: This paper presents comprehensive consensus guidelines for the treatment of dermatitis in patients
with SCCHN receiving EGFR inhibitors in combination with radiotherapy.
Key words: cetuximab, EGFR inhibitors, radiation dermatitis, radiotherapy, skin reactions, squamous cell carcinoma
of the head and neck
introduction
External beam radiotherapy is the main nonsurgical treatment
in patients with locoregionally advanced head and neck cancers.
The acute side-effects of radiation therapy are well documented
and include dermatitis, mucositis, xerostomia, weight loss,
dysphagia, taste alteration, nausea and vomiting, pain and
asthenia. When given without chemotherapy, altered
fractionation regimens, including accelerated and
hyperfractionated regimens, alone or combined [1], have
largely replaced conventional radiation fractionation (70 Gy in
2 Gy fractions over a 7-week period). Reducing overall
treatment time and/or increasing total radiation dose have
improved locoregional control, although effects on overall
survival were less significant [1, 2]. The improvements in
locoregional control, however, are achieved at the expense of an
increase in acute toxicity [1–3]. In a randomised phase III
Radiation Therapy Oncology Group (RTOG) study (RTOG
9003), the incidence of grade 3 or worse acute side-effects was
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35% for conventional fractionation and 54.5%, 50.4% and
58.8% for hyperfractionation, split-course accelerated
fractionation and accelerated fractionation with concomitant
boost, respectively [1].
radiation dermatitis
Radiation dermatitis is experienced, to various degrees, by the
majority of patients undergoing radiotherapy for locoregionally
advanced head and neck cancer (Table 1) [1, 2, 4–8]. In most
patients, the radiation dermatitis is mild to moderate (grades 1
and 2), but 20%–25% of patients experience severe reactions
[9]. The incidence of severe reactions is dependent on the total
radiation dose, the dose per fraction, the overall treatment time,
beam type and energy and the surface area of the skin that is
exposed to radiation [10]. In the RTOG 9003 study, the rates of
acute grade 3/4 skin toxicity were slightly higher with
hyperfractionation (11%) and accelerated fractionation with
concomitant boost (11%) compared with standard fractionation
(7%). It is well recognised that the addition of chemotherapy to
radiotherapy (chemoradiotherapy) increases the acute side-effect
profile of treatment [6, 11], particularly when combined with
altered fractionation regimens. In a recently reported phase III
study, in which the majority of patients received > 60 Gy with
concomitant boost regimen, and 53% of patients also received
chemoradiotherapy [12], the mean rates of grades 2, 3 and 4
radiation dermatitis were 54%, 20% and 4%, respectively [12].
The authors contrasted these rates with the corresponding rates
of 49%, 8% and 0% observed over all arms of the RTOG 9003
study [1, 12]. The severity of acute reactions has been shown
both to lead to enhanced late effects and to impact adversely on
cosmesis, especially in patients with infected irradiated skin [13].
Finally, an association between the occurrence of radiation
dermatitis and patient quality of life has been observed [12], and
the impact of this on the well-being of the patient should not be
underestimated.
grading of radiation dermatitis
Radiation dermatitis generally manifests within a few weeks
after the start of radiotherapy. Its onset varies depending on the
radiation dose intensity and the normal tissue sensitivity of
individuals. As the cumulative dose of radiation increases, the
transient erythema occurring during the first weeks of
radiotherapy may evolve into the more persistent erythema to
dry or even moist desquamation that reflects the damage to the
basal cell layer and the sweat and sebaceous glands. A number
of different systems have been developed by various
organisations over the years (see Table 1), including the
National Cancer Institute (NCI), the RTOG, World Health
Table 1. Incidence of grade 3+ radiation-associated skin toxic effects in patients receiving different radiotherapy regimens for head and neck cancers in
randomised phase III trials
Type of RT Dosing regimen N Toxicity
grading
scale
Grade 0–2
skin toxicity
(%)
Grade ‡ 3
skin toxicity
(%)
References
Conventional 70 Gy (35 2-Gy fractions in 7 weeks) 113 EORTC 47 11 (grade 3) Calais et al. [5]
129 RTOG 73 27 (epidermitis) Bourhis et al. [2]
268 RTOG 94 7 (grade 3) Fu et al. [1]
Accelerated RT 70.2 Gy (39 1.8-Gy fractions in 51 days)
three cycles of 23.4 Gy each,
separated by a rest period of 11 days
140 WHO Not reported 6.4 (grade 3),
0.7 (grade 4)
Wendt et al. [6]
Accelerated RT
with split
67.2 Gy (42 1.6-Gy fractions b.i.d.,
5 days/week in 6 weeks including
a 2-week rest after 38.4 Gy)
274 RTOG 85 3 (grade 3) Fu et al. [1]
Very accelerated RT 62–64 Gy (31–32 2-Gy fractions in
23 days)
137 RTOG 66 33 (epidermitis) Bourhis et al. [2]
Accelerated RT with
concomitant boost
72 Gy (42 1.8-Gy fractions,
5 days/week >6 weeks with
concomitant boost of
1.5 Gy/fraction/day for the
final 12 treatment days)
268 RTOG 85 11 (grade 3) Fu et al. [1]
Hyperfractionated RT 81.6 Gy (68 1.2-Gy fractions b.i.d.,
5 days/week in 7 weeks)
263 RTOG 81 11 (grade 3),
<1 (grade 4)
Fu et al. [1]
Hyperfractionated
accelerated RT
77.6 Gy in 6 weeks (2.0 Gy q.i.d.
to 14 Gy then 1.4 Gy b.i.d.)
177 EORTC Not reported 46 (grade 3/4) Budach et al. [7]
IMRT (not randomised) Definitive IMRT (n = 52)a: mean dose
64.34–72.64 Gy; postoperative IMRT
(n = 74): 60.95–68.53
126 RTOG 75 18 (grade 3),
7 (grade 4)
Chao et al. [8]
Unless otherwise stated, data are presented only for the trial arms in which patients received RT alone.
aThirty five patients received concomitant cisplatin.
EORTC, European Organisation for Research and Treatment of Cancer; IMRT, intensity-modulated radiotherapy; RT, radiotherapy; RTOG, Radiation
Therapy Oncology Group; WHO, World Health Organisation.
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Organisation and the European Organisation for Research and
Treatment of Cancer, to describe the spectrum of radiation
dermatitis. The need for the development and implementation
of meaningful and reliable reporting methods for recording and
reporting the toxicity of cancer treatment, which will also
enable the comparison of toxicity between centres, is well
recognised [14]. Of the currently available toxicity criteria,
those introduced by the NCI in 2003 [NCI—Common
Terminology Criteria for Adverse Events (NCI CTCAE),
version 3] are considered to be the most comprehensive
method [14, 15]. The grading of radiation dermatitis according
to these criteria is shown in Table 2.
pathophysiological characteristics of radiation
dermatitis
Irradiation of the skin leads to a complex pattern of direct
tissue injury and inflammatory cell recruitment, involving
damage to epidermal basal cells, endothelial cells and vascular
components and a reduction in Langerhans cells [10] (and
references contained therein). Radiation-induced keratinocyte
damage induces DNA injury repair via activation of the p53
pathway and a simultaneous release of inflammatory cytokines
as a consequence of the generation of free radicals. The main
cytokines involved in this reaction are interleukins 1 and 6,
tumour necrosis factor-a and transforming growth factor-b
[16]. At the same time, keratinocytes demonstrate increased
expression of epidermal growth factor receptor (EGFR),
possibly as a mechanism for repopulating irradiated areas [17].
The up-regulation of EGFR may alter the cells interaction with
EGFR inhibition, although cetuximab in combination with
radiation has not exacerbated radiation dermatitis in clinical
trials to date [9]. In severe radiation dermatitis, there is massive
neutrophilic infiltration of the epidermis and profound
apoptosis. With successive doses of radiation, the opportunity
for tissue healing due to cellular repopulation is reduced, even
over weekend interruptions of daily fractionated radiotherapy,
thereby compounding the insult. Chronic radiation-induced
changes in the skin are characterised by the disappearance of
follicular structures, an increase in collagen and damage to
elastic fibres in the dermis, and a fragile epidermal covering.
EGFR inhibitors in squamous cell
carcinoma of the head and neck
EGFR inhibitors are increasingly being used in a range of
tumour types in combination with standard therapies in an
attempt to improve outcome. In 2006, the results of
a randomised phase III study demonstrated that the addition of
the EGFR-targeted IgG1 mAb, cetuximab, to radiotherapy
resulted in statistically significant and clinically meaningful
improvements in the duration of locoregional control and
median overall survival versus radiotherapy alone in the
treatment of locoregionally advanced squamous cell carcinoma
of the head and neck (SCCHN) [9]. This study led to the
regulatory approval in a number of countries of cetuximab plus
radiotherapy in this setting.
skin reactions associated with EGFR inhibitors
EGFR inhibitor use can be associated with the development of
skin reactions, including a macular, papular, pustular rash,
commonly referred to as acne-like rash (or folliculitis); xerosis;
fissures; telangiectasia; hyperpigmentation and hair and nail
changes [18]. The most common skin reaction is the acne-like
rash [18, 19], which is generally distributed in areas rich in
sebaceous glands, such as the face, neck and retroauricular area,
the shoulders, the upper trunk (V-shaped) and the scalp [18].
The acne-like rash comprises itchy erythematous follicular
papules that may evolve into pustules which may conflate [18].
Other presentations include: diffuse erythema with follicular
papulopustules and telangiectasia, a seborrhoeic dermatitis-like
rash or, occasionally, an oedematous facial erythema [18]. In
the absence of radiation, the acne-like rash can be seen within
a few days of the commencement of treatment and peaks at 2–3
weeks after starting therapy. In some cases, the rash can be
delayed, and in others flares can occur at each subsequent
administration of the EGFR inhibitor. The majority of skin
reactions seen with cetuximab are grade 1 or 2 (80%) [20]
and often resolve without the need for specialised treatment.
The pathophysiology of the skin reactions associated with
EGFR inhibitors is still not well understood [21]. The EGFR is
expressed at high levels in the epidermis and in the hair follicle,
particularly in the proliferative basal cell layers, and EGFR is
known to be essential to the regulation of several aspects of
normal keratinocyte biology, including cell cycle progression,
differentiation, cell movement and cellular survival [22].
Systemic administration of cetuximab results in up-regulation
of the negative growth regulator, p27kip, in epidermal
keratinocytes, possibly leading to impairment of cell growth
and differentiation [23]. In patients developing EGFR
inhibitor-associated acne-like rash, basal keratinocytes in the
epidermis and hair follicles display high levels of p53. In
addition, inflammation is commonly found in the epidermal–
dermal junction, accompanied by neutrophilic infiltration and
damage to hair follicles.
Table 2. Toxicity grading of radiation dermatitis according to the National Cancer Institute—Common Terminology Criteria for Adverse Events
(version 3) [15]
Adverse event Short name Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Rash: dermatitis
associated with
radiation
Dermatitis Faint erythema or
dry desquamation
Moderate to brisk
erythema; patchy
moist desquamation,
mostly confined to
skin folds and creases;
moderate oedema
Moist desquamation
other than skin folds
and creases; bleeding
induced by minor
trauma or abrasion
Skin necrosis or ulceration
of full thickness dermis;
spontaneous bleeding
from involved site
Death
original article Annals of Oncology
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Beneficial topical treatment approaches include anti-
inflammatory or antibiotic medication, supplemented with
saline compresses for grade 3 reactions [18], oral tetracyclines
for grade 2+ reactions, with an appropriate antibiotic for
Staphylococcus aureus superinfection, and oral antihistamines to
reduce pruritus. The long-term use of corticosteroids is
generally avoided due to their potential to induce or exacerbate
acne and other skin conditions and to interfere with the
antibody-dependent cell-mediated cytotoxicity reactions thought
to contribute to the antitumour effects of cetuximab [18].
radiation dermatitis in patients
receiving radiotherapy and EGFR
inhibitors
Considering the fact that radiation is known to up-regulate
EGFR in unirradiated skin, it would appear possible that there
is some biological interplay between the pathophysiological
effects of radiation on the skin and those of EGFR inhibitors.
Coupled with preclinical findings showing that cetuximab
demonstrates marked synergy with radiation in cancer cell lines
and tumour models [24–26], the effect on the skin of
a combination of cetuximab and radiation is of considerable
interest, as it might require special care to reduce symptoms
and severity. Interestingly, radiation appears to delay the onset
of the cetuximab-induced acne-like rash. The cetuximab-
associated acne-like rash typically appears within irradiated
fields 3–5 weeks after initiation of treatment [27]. There
appears to be no obvious relationship between the severity of
cetuximab-associated acne-like rash outside irradiated fields
and the severity of radiation dermatitis.
The phase III randomised trial comparing radiotherapy with
or without cetuximab in locoregionally advanced SCCHN
revealed no statistically significantly increase in the incidence or
severity of radiation dermatitis compared with radiotherapy
alone (Table 3) [9]. The incidence of grade ‡ 3 radiation
dermatitis was 18% with radiotherapy alone and 23% with
radiotherapy plus cetuximab (P = 0.27). There was a slight
increase in the median duration of radiation dermatitis in the
cetuximab arm (11.1 weeks) compared with the radiotherapy-
alone arm (9.4 weeks) [27].
the management of radiation dermatitis
in patients receiving radiotherapy and
EGFR inhibitors
Centres at which radiotherapy is routinely administered for
the treatment of SCCHN have institutional policies on the
management of radiation dermatitis. Gentle washing and
drying of the skin within the radiation portal have been
shown to reduce the acute radiotherapy-associated skin
reactions in patients receiving radiotherapy for breast cancer
and is now routinely recommended for all patients receiving
radiotherapy [28, 29]. Beyond that, there is little evidence to
support the use of one topical approach over another, as
highlighted by recent literature reviews of trials investigating
the prophylaxis and treatment of radiation dermatitis for
various tumour types [30, 31]. The recently reported results of
an RTOG trial (99-13) in patients with SCCHN failed to show
any benefit of the systematic use of interventional or
prophylactic trolamine emulsion in reducing grade 2 or
higher skin toxicity [12]. Another study showed no
Table 3. Incidence of grade 3/4 radiation dermatitis with radiotherapy 6 cetuximab in locoregionally advanced squamous cell carcinoma of the head and
neck: data from a randomised phase III trial [9]
Type of RT Dosing regimen N = 424 All grades (%) Grade ‡ 3 (%)
RT alone
(N = 212)
RT + cetuximab
(N = 208)
RT alone
(N = 212)
RT + cetuximab
(N = 208)
Once daily 70 Gy (35 2-Gy fractions
in 7 weeks)
26%
90 86 18 23
Twice daily 72–76.8 Gy in 60–64 fractions
(10 1.2-Gy fractions for
6–6.5 weeks)
18%
Concomitant boost 72 Gy in 42 fractions
(Once-daily fractions;
1.8 Gy/fraction;
5 fractions/week for
3.6 weeks: twice-daily
fractions; AM 21.6 Gy,
1.8 Gy/fraction,
5 fractions/week for
2.5 weeks. PM 18.0 Gy,
1.5 Gy/fraction,
5 fractions/week for
2.4 weeks)
56% P = 0.24a P = 0.27a
Toxicity assessed using Radiation Therapy Oncology Group toxicity scale; P value determined with the use of Fisher’s exact test.
RT, radiotherapy.
aRT alone vs RT + cetuximab, where RT includes once daily, twice daily and concomitant boost regimens.
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significant benefit of pentoxifylline prophylaxis on the
development of acute skin reactions [32]. The potential benefit
of oral zinc supplementation in postponing the development of
severe mucositis and dermatitis, and in alleviating the degree of
mucositis and dermatitis, in patients receiving radiotherapy for
cancers of the head and neck [33] warrants additional
confirmatory studies.
The goal of the advisory board meeting reported here was to
develop consensus guidelines to help physicians effectively
manage radiation dermatitis in patients receiving radiotherapy
and concurrent EGFR inhibitor treatment for SCCHN. The
advisory board panel comprised 11 specialists from seven
countries in the fields of radiation and medical oncology and
dermatology.
The major aim of managing skin reactions within irradiated
areas is to minimise modification of the prescribed
radiotherapy and/or EGFR inhibitor regimens, which might
compromise efficacy. It is important to recognise that the
choice of radiotherapy dose and schedule is at the discretion of
the radiation oncologist and should not be influenced, in the
absence of compelling data, by the concomitant administration
of the EGFR inhibitor. While there is an increase in acute
toxicity associated with altered fractionation, relative to
conventional fractionation, there are no data to indicate that
EGFR inhibitors, such as cetuximab, cannot be used with
altered fractionation regimens. In fact, a majority of patients
received altered fractionation regimens in combination with
cetuximab in the recent phase III trial comparing combination
treatment with radiotherapy alone [9].
General management of radiation dermatitis is presented
along with treatment measures according to the NCI CTCAE
(version 3) grading of dermatitis (Table 4), divided into three
categories, i.e. grade 1, grades 2–3 and grade 4.
General management
 While the development of some degree of radiation dermatitis
is considered inevitable for the majority of patients receiving
radiotherapy, the establishment of a proper technique to
minimise the dose delivered to the epidermis and a quality
assurance programme for radiotherapy planning and delivery
is critical not only in therapeutic terms but also from the
perspective of avoiding unnecessary skin toxicity.
 A primary step in the management of radiation dermatitis of
any grade is to establish that the skin reactions are not
a result of any concomitant medication, other than the EGFR
inhibitor. In the case of more severe skin reactions, it should
also be verified that radiation dose and distribution are
correct.
Following these actions, a number of steps, irrespective of the
grade of radiation dermatitis, can be followed.
 It is recommended that the institutional policy for skin
preparation before radiotherapy be adopted for patients
scheduled to receive an EGFR inhibitor and radiotherapy.
Patients should be encouraged to maintain good standards of
hygiene. The irradiated area should be kept clean to
minimise the risk of infection. Patients should wash the area
with a gentle cleanser and dry it with a soft, clean towel. The
use of a pH-neutral synthetic detergent is preferable to soap,
which can irritate the skin.
 Topical treatment approaches may offer symptomatic relief
and may help skin healing. Different areas of skin may
require different treatment approaches.
 Drying pastes may be appropriate for use within skin folds,
where skin reactions remain moist.
 Gels can be useful in seborrhoeic areas.
 Creams can be used in areas outside skin folds and
seborrhoeic areas.
 Hydrophilic dressings may also be useful in moist areas.
These are placed over the cleaned, dried wound and some
can absorb wound exudate. They can be soothing for the
patient and can help skin healing.
 Greasy topical products should be avoided because they
inhibit the absorption of wound exudate and promote
superinfection.
Topical moisturisers, gels, emulsions and dressings should
not be applied shortly before radiation treatment as they can
cause a bolus effect, thereby artificially increasing the radiation
dose to the epidermis. It is important to instruct patients to
gently clean and dry the skin in the radiation field before each
irradiation session.
 While the use of corticosteroids, often applied in some
centres during the course of radiotherapy in head and
neck cancer patients, is not contra-indicated in the
presence of radiation dermatitis, it is suggested that the
overall treatment time of any corticosteroid-containing
treatment be limited.
 Pain relief for skin reactions should be considered in the
context of any pain relief medication the patient may already
be receiving in the course of their treatment, for instance, for
mucositis.
 Patients should be advised to avoid:
 Sun exposure wherever possible. This can be achieved by
using soft clothing to cover the area and/or the use of
mineral sunblocks.
 The use of skin irritants, such as perfumes, deodorants or
alcohol-based lotions.
 Scratching of the skin in the affected area.
 General guidance on the treatment of cetuximab-associated
skin reactions developing outside the irradiated area was
reported elsewhere [18–20].
prophylaxis
There is currently no evidence that prophylactic treatments,
beyond keeping the irradiated area clean and dry, are effective in
reducing the incidence or severity of radiation dermatitis [31].
grade 1 radiation dermatitis
The NCI CTCAE (version 3.0) definition of grade 1 radiation
dermatitis is faint erythema or dry desquamation [15]. Grade 1
original article Annals of Oncology
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Table 4. Grade-specific management of radiation dermatitis in patients with squamous cell carcinoma of the head and neck receiving radiotherapy and cetuximab: a summary
Grade of radiation dermatitis Grade 1 Grade 2 Grade 3 Grade 4
Definition of radiation
dermatitis (NCI CTCAE, v3.0)
Faint erythema or dry
desquamation
Moderate to brisk erythema;
patchy, moist desquamation,
mostly confined to skin
folds and creases; moderate
oedema
Moist desquamation other
than skin folds and creases;
bleeding induced by minor
trauma or abrasion
Skin necrosis or ulceration of full
thickness of dermis; spontaneous
bleeding from involved site
General management
approaches
See General management
Maintain hygiene and gently clean and dry skin in the radiation field shortly before radiotherapy
Topical moisturisers, gels, emulsions and dressings should not be applied shortly before radiation treatment
as they can cause a bolus effect, thereby artificially increasing the radiation dose to the epidermis
Grade-specific management
approaches
Use of a moisturiser is
optional
Keep the irradiated area clean, even when ulcerated Verify that radiation dose and
distribution are correct
If anti-infective measures
are desired, antibacterial
moisturisers (e.g. triclosan
or chlorhexidine-based
cream) may be used
occasionally
In the absence of clinical signs of infection, one or combinations
of the following topical approaches may be used:
Requires specialised wound care
with the assistance of the
radiation oncologist, dermatologist
and nurse, and should be treated
on a case by case basis
 Drying gels, possibly with the addition of antiseptics (e.g.
chlorhexidine-based creams)
 An anti-inflammatory emulsion, such as trolamine
 Hyaluronic acid cream
 Hydrophilic dressings, applied after radiotherapy to the cleaned,
irradiated area, which may provide
symptomatic
 Zinc oxide paste, if easy to remove prior to radiotherapy
 When used, silver sulfadiazine or beta glucan cream should be applied
after radiotherapy
(possibly in the evening) after cleaning the irradiated area
 Where infection is suspected:
 The treating physician should use best clinical judgement for identifying
infection, including the consideration of swabbing the area for
identification of the infectious agent
 Topical antibiotics (should not be used prophylactically)
 Doxycycline is not recommended at this stage
 Blood granulocyte counts should be checked, particularly if the patient
is receiving concomitant chemotherapy
 Blood cultures should be carried out if there
are additional signs of sepsis and/or fever
Management team Can be managed primarily by
nursing staff
Can be managed by an integrated management team comprising the radiation
oncologist, nurse, medical oncologist (where appropriate) and
dermatologist, as required
Should be managed primarily by
a wound specialist, with the
assistance of the radiation
oncologist, medical oncologist
(where appropriate), dermatologist
and nurse, as required
Skin reactions should be assessed at least once a week
Please see text for full details. NCI CTCAE, National Cancer Institute—Common Terminology Criteria for Adverse Events.
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radiation dermatitis requires no specific treatment. Indeed, the
most important step is to keep the area clean between
treatments. The subsequent use of a nonperfumed moisturiser
is optional. Moisturisers containing antibacterials (e.g.
chlorhexidine or triclosan) can be used occasionally if anti-
infective measures are considered appropriate. Overtreatment,
including overuse of antiseptic creams, can irritate the skin. In
general, skin reactions at this grade can be managed primarily
by the nursing staff.
grades 2 and 3 radiation dermatitis
According to the NCI CTCAE (version 3.0) classification, grade
2 radiation dermatitis includes moderate to brisk erythema,
patchy moist desquamation mostly confined to skin folds and
creases and moderate oedema [15]. Grade 3 radiation
dermatitis consists of moist desquamation other than skin folds
or creases and bleeding induced by minor trauma or abrasion [15].
In grades 2 and 3 radiation dermatitis, as with grade 1, the
irradiated area should be cleaned and dried, even when
ulcerated. A number of topical applications can be considered.
Examples are drying gels, with the addition of antiseptics if
considered appropriate (e.g. chlorhexidine-based creams, but
not chlorhexidine in alcohol), hydrophilic dressings, an anti-
inflammatory emulsion (e.g. trolamine, hyaluronic acid cream)
and zinc oxide paste, if considered sufficiently easy to remove
before radiotherapy. Silver sulfadiazine or beta glucan cream
may also be useful (but should only be applied after
radiotherapy, possibly in the evening, after cleaning the
irradiated area).
Where infection is suspected, the treating physician should
use best clinical judgement for management, including
considering swabbing the affected area for identification of the
infectious agent. Topical antibiotics should be reserved for
superinfection and should not be used prophylactically.
Doxycycline is not recommended at this stage. In patients in
whom skin infection is suspected or documented, the blood
granulocyte count should also be checked, especially if the
patient is also receiving concomitant chemotherapy. Indeed,
severe desquamation is associated, in a number of cases, with
a risk of septicaemia. Blood cultures should also be carried out
if additional signs of sepsis and/or fever are present, particularly
if the granulocyte count is low.
Grades 2 and 3 radiation dermatitis can be managed by an
integrated team comprising the radiation oncologist, medical
oncologist (where appropriate), nurse and dermatologist, as
required. Skin reactions should be assessed at least once a week.
grade 4 radiation dermatitis
Grade 4 radiation dermatitis is defined by the NCI CTCAE
(version 3.0) as skin necrosis or ulceration of full thickness
dermis; spontaneous bleeding from the involved site [15].
Grade 4 radiation dermatitis is relatively rare, generally
occurring in <5% of patients receiving radiotherapy for
SCCHN. This stage of radiation dermatitis requires specialised
wound care and should be treated on a case-by-case basis.
Grade 4 radiation dermatitis should be managed primarily by
a wound specialist, with the assistance of the radiation
oncologist, medical oncologist (where appropriate),
dermatologist and nurse, as required.
the management of coexisting radiation
dermatitis and EGFR inhibitor-related
acne-like rash within irradiated fields
Where there is coexistence of radiation dermatitis and EGFR
inhibitor-related acne-like rash within an irradiated field,
management depends on the grade of radiation dermatitis:
 For grade 1 radiation dermatitis (or no radiation dermatitis),
it is prudent to follow the published general guidelines on the
management of EGFR inhibitor-related acne-like rash
outside irradiated fields [18–20].
 For grade 2 or higher radiation dermatitis, it is preferable to
adhere to the management recommendations for radiation
dermatitis, as outlined in this manuscript.
issues to be addressed
One of the problems hindering the effective reporting and
management of acute radiation toxic effects, including
radiation dermatitis, is, as discussed earlier, the use of varied,
inconsistent toxicity criteria. The adoption of the NCI CTCAE
version 3 by an increasing number of institutions is a step
forward in achieving consistency in toxicity reporting.
However, even with the use of standardised criteria, grading of
reactions remains subjective and this will impede the
interpretation of toxicity findings between clinical studies. One
way to minimise discrepancy is to document skin toxicity
photographically, thus enabling subsequent independent
confirmation of gradings where necessary. It is recommended
that digital photographic documentation be adopted as
a standard practice in clinical trials.
It is clear that while commonly used topical products may
help to manage the symptoms of radiation dermatitis and
EGFR inhibitor-associated acne-like rash, there is little evidence
to indicate that any of the currently available products can
prevent the development of these skin reactions. Recently, the
topical application of vitamin K3 (menadione), an EGFR
phosphatase inhibitor, was shown to restore EGFR-mediated
signalling in the skin secondary to systemic administration of
the EGFR inhibitors, erlotinib and cetuximab [34]. In view of
this, it would be interesting to formally test whether
prophylactic application of menadione within a radiation field
would alter the incidence, intensity and/or characteristics of
EGFR inhibitor-associated acne-like rash developing within the
irradiated field in patients receiving cetuximab and
radiotherapy.
A greater understanding of the biological mechanisms
responsible for the skin toxicity of the individual agents would
lead to the development of rational and more effective
management strategies for the skin reactions of patients
receiving radiotherapy and EGFR inhibitors. The toxicity of the
combination of cetuximab and radiotherapy in the clinical
setting is being further studied in preclinical models and is
being monitored in the ongoing pharmacovigilance
original article Annals of Oncology
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programme. In addition, results from clinical trials currently
being conducted by, among others, the RTOG and the French
radiotherapy oncology group for head and neck cancer should
provide more information on any toxicity interactions between
the two treatments.
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